This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Dr. David Gauden, a co-founder of Blue Earth Diagnostics and with the company since 2014, assumes the role of full-time CEO of Bracco subsidiary Blue Earth Therapeutics. Blue Earth Diagnostics, an indirect subsidiary of Bracco Imaging S.p.A., Bracco Imaging S.p.A., Board of Directors.
Magneticresonanceimaging will help to evaluate ligamentous injury and provides a 94% predictive value for diagnosing Lisfranc injury [5]. It is useful when measuring M2-C1 distance and comparing the sides of the foot [8]. Treatment: Non-surgical treatment can only be considered for stable, non-displaced injuries.
0000000000001232 Cerebral small vessel disease (CSVD) is one of the most common clinical conditions that a neuroimager will encounter. CSVD is associated with an increased risk of clinical ischemic and hemorrhagic stroke, silent infarcts, and cognitive decline and dementia. Continuum (Minneap Minn). 2023;29(2):501-518. doi:10.1212/CON.0000000000001232
A 2014 pooled analysis of 21 studies from 1993 to 2013 showed CTA has a sensitivity of 83.2% 5,16] Algorithms translate detected changes in MTT, CBV, and CBF into images that can be used in clinical decision-making. 2014 Nov 29;384(9958):1929-35. Quant Imaging Med Surg. 2014 Aug;4(4):282-90. Mancall EL.
We organize all of the trending information in your field so you don't have to. Join 5,000 users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content